Ser375
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser375  -  Pyk2 (human)

Site Information
KDGEKRNsLPQIPML   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 468542

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 )
Disease tissue studied:
breast cancer ( 2 , 3 , 11 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 2 ) , colorectal cancer ( 24 ) , colorectal carcinoma ( 24 ) , leukemia ( 12 , 13 , 21 ) , acute myelogenous leukemia ( 12 , 13 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 10 , 12 ) , acute megakaryoblastic leukemia (M7) ( 10 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 10 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 10 ) , acute myeloblastic leukemia, without maturation (M1) ( 10 ) , chronic myelogenous leukemia ( 21 ) , lung cancer ( 11 , 24 ) , non-small cell lung cancer ( 11 ) , lymphoma ( 4 ) , B cell lymphoma ( 10 ) , Burkitt's lymphoma ( 4 ) , non-Hodgkin's lymphoma ( 10 ) , follicular lymphoma ( 4 ) , mantle cell lymphoma ( 4 ) , ovarian cancer ( 2 ) , multiple myeloma ( 10 )
Relevant cell line - cell type - tissue:
A498 (renal) ( 15 ) , A549 (pulmonary) ( 6 , 24 ) , AML-193 (monocyte) ( 10 , 12 ) , BJAB (B lymphocyte) ( 4 ) , breast ( 1 , 2 ) , BT-20 (breast cell) ( 11 ) , BT-549 (breast cell) ( 11 ) , Calu 6 (pulmonary) ( 11 ) , CMK (megakaryoblast) ( 10 ) , CTS (myeloid) ( 10 ) , DOHH2 ('B lymphocyte, precursor') ( 10 ) , FL-18 (B lymphocyte) ( 4 ) , FL-318 (B lymphocyte) ( 4 ) , H2009 (pulmonary) ( 11 ) , H2077 (pulmonary) ( 11 ) , H2887 (pulmonary) ( 11 ) , H322M (pulmonary) ( 11 ) , HCC1359 (pulmonary) ( 11 ) , HCC1937 (breast cell) ( 11 ) , HCC2279 (pulmonary) ( 11 ) , HCC366 (pulmonary) ( 11 ) , HCC4006 (pulmonary) ( 11 ) , HCC78 (pulmonary) ( 11 ) , HCC827 (pulmonary) ( 11 ) , HCT116 (intestinal) ( 19 , 24 ) , HEL (erythroid) ( 10 , 12 ) , HeLa (cervical) ( 9 ) , HeLa S3 (cervical) ( 20 ) , HeLa_Meta (cervical) ( 14 ) , HeLa_Pro (cervical) ( 14 ) , HeLa_Telo (cervical) ( 14 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 3 ) , HMLER ('stem, breast cancer') ( 3 ) , HOP62 (pulmonary) ( 11 ) , JEKO-1 (B lymphocyte) ( 4 ) , Jurkat (T lymphocyte) ( 7 , 16 , 22 , 24 ) , K562 (erythroid) ( 9 , 18 , 21 ) , Kasumi-1 (myeloid) ( 10 ) , KG-1 (myeloid) ( 10 , 13 ) , LCLC-103H (pulmonary) ( 11 ) , leukocyte-blood ( 17 ) , liver ( 5 ) , LOU-NH91 (squamous) ( 11 ) , MCF-7 (breast cell) ( 11 ) , MDA-MB-231 (breast cell) ( 11 ) , MDA-MB-435S (breast cell) ( 19 ) , MDA-MB-468 (breast cell) ( 11 ) , MV4-11 (macrophage) ( 10 , 19 ) , NCEB-1 (B lymphocyte) ( 4 ) , NCI-H1395 (pulmonary) ( 11 ) , NCI-H1568 (pulmonary) ( 11 ) , NCI-H157 (pulmonary) ( 11 ) , NCI-H1648 (pulmonary) ( 11 ) , NCI-H1666 (pulmonary) ( 11 ) , NCI-H2030 (pulmonary) ( 11 ) , NCI-H2172 (pulmonary) ( 11 ) , NCI-H322 (pulmonary) ( 11 ) , NCI-H460 (pulmonary) ( 11 ) , NCI-H520 (squamous) ( 11 ) , NCI-H647 (pulmonary) ( 11 ) , OCI-ly1 (B lymphocyte) ( 4 ) , OPM-2 (plasma cell) ( 10 ) , ovary ( 2 ) , P31/FUJ (erythroid) ( 10 ) , PC9 (pulmonary) ( 11 ) , platelet-blood ( 23 ) , Raji (B lymphocyte) ( 4 ) , RAMOS (B lymphocyte) ( 4 ) , REC-1 (B lymphocyte) ( 4 ) , RL ('B lymphocyte, precursor') ( 10 ) , RPMI-8266 (plasma cell) ( 10 ) , SU-DHL-4 (B lymphocyte) ( 4 ) , SU-DHL-6 (B lymphocyte) ( 10 ) , U266 (plasma cell) ( 10 ) , UPN-1 (B lymphocyte) ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

4

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

5

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

6

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

7

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

8

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

9

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

10

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

11

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

12

Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66
22547687   Curated Info

13

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

14

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

15

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

16

Possemato A (2010) CST Curation Set: 9348; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V)
Curated Info

17

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

18

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

19

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

20

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

21

Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

22

Stokes M (2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

23

Zahedi RP, et al. (2008) Phosphoproteome of resting human platelets. J Proteome Res 7, 526-34
18088087   Curated Info

24

Wissing J, et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6, 537-47
17192257   Curated Info